

REFERENCES

1. Stewart LA, Parmar MKB
Meta-analysis of the literature or of individual patient data : is there a difference?
Lancet 341:418-422, 1993
2. Andersen JW, Harrington D
Meta-analyses need new publication standards.
J.Clin.Oncol.10(6):878-880, 1992
3. Buyse M
Meta-analysis, use and misuse.
J.Clin.Oncol. 11(2):382, 1993
4. Freiman JA, Chalmers TC, Smith H, Kuebler RR
The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial.
NEJM 299:690-694, 1978
5. Braitman LE
Statistical power analysis in medical research.
Ann.Int.Med.99(2):269-271, 1983
6. Baar J, Tannock I
Analysing the same data in two ways : A demonstration model to illustrate the reporting and misreporting of clinical trials.
J.Clin.Oncol. 7:969-978, 1989
7. Pocock SJ
When to stop a clinical trial
BMJ. 305:235-240, 1992
8. Department of Clinical Epidemiology and Biostatistics, McMaster University
How to read clinical journals. I. Why read them and how to start reading them critically.
CMAJ 124:555-558, 1981
9. Department of Clinical Epidemiology and Biostatistics, McMaster University
How to read clinical journals. II. To learn about a diagnostic test.
CMAJ 124:703-710, 1981
10. Department of Clinical Epidemiology and Biostatistics, McMaster University
How to read clinical journals. III. To learn the clinical course and prognosis of disease.
CMAJ 124:869-872, 1981
11. Department of Clinical Epidemiology and Biostatistics, McMaster University
How to read clinical journals. IV. To determine etiology or causation.
CMAJ 124:985-990, 1981
12. Department of Clinical Epidemiology and Biostatistics, McMaster University
How to read clinical journals. V. To distinguish useful from useless or even harmful therapy.
CMAJ 124:1156-1162, 1981
13. The Editors
Guidelines for writing papers.
BMJ 294:36-38, 1987
14. Berry G
Statistical Guidelines and Statistical Guidance.
MJA 146:408-409, 1987
15. Chalmer TC, Smith H, Blackburn B, Silverman B, Schroeder B, Reitman D, Ambroz A
A method for assessing the quality of a randomized control trial.
Control.Clin.Trails 2:31-49, 1981
16. Miller AB, Hoogstraten B, Staquet M, Winkler A
Reporting results of cancer treatment.
Cancer 47:207-214, 1981
17. Altman DG, Gore SM, Gardner MJ, Pocock SJ
Statistical guidelines for contributors to medical journals.
BMJ. 286:1489-1493, 1983
18. Zelen M
Guidelines for publishing papers on cancer clinical trials : responsibilities of editors and authors.
J.Clin.Oncol.1(2):164-169, 1983
19. Bailar JC, Mostellar F
Guidelines for statistical reporting in articles for medical journals. Amplifications and explanations.
Ann.Int.Med.108:266-273, 1988
20. DerSimonian R, Charette LJ, McPeck B, Mosteller F
Reporting on methods in clinical trials.
NEJM 306:1332-1337, 1982
21. Simon R, Wittes RE
Methodologic guidelines for reporting of clinical trials.
Cancer Treat.Report 69(1):1-3, 1985
22. Lagios MD, Wertdahl PR, Margolin FR et al
Duct carcinoma in situ.
Cancer 50:1309-1314, 1982
23. Fourquet A, Zafrani B, Campani F, Durand JC, Vilcoq JR
Breast Conserving treatment for Ductal Carcinoma in situ.
Semin.Rad.Oncol.2(2):116-124, 1992
24. Rosen PP, Senie R, Schottenfeld D, et al
Non-invasive breast carcinoma. Frequency of unsuspected invasion and implications for treatment.
Ann.Surg.189:377-382, 1979
25. Holland R, Hendricks JHCL, Verbeek ALM, et al
Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ.
Lancet 35:519-522, 1990
26. Lagios MD
Ductal carcinoma in situ. Pathology and treatment.
Surg.Clin.North Am.70:853-871, 1990
27. Fisher B, Costantino J, Redmond C, Fisher E, Margolese R, Dimitrov N, Wolmark N, Wickerham DL, Deutsch M, Ore L, Mamounas E, Poller W, Kavanah M.
Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer.
NEJM 328(22):1581-1586, 1993
28. Simon RM
Design and conduct of clinical trials.
In De Vita VT, Hellman S, Rosenberg SA (eds): Cancer : Principles and Practice of Oncology, pp396-420. 3rd Edition. Lippincott, Philadelphia, 1989.
29. Casagrande JT, Pike MC, Smith PG

- An improved approximate formula for calculating sample sizes for comparing two binomial distributions. *Biometrics* 34:483-486, 1978
30. Lewis JA, Machin D
Intention to treat - who should use ITT? *Br.J.Cancer* 68:647-650, 1993
31. Angell M, Kassirer JP
Setting the record straight in the Breast-Cancer trials. *NEJM* 330(20):1448-1450, 1994
32. Schwartz GF
The role of excision and surveillance alone in subclinical DCIS of the breast. *Oncology* 8(2):21-35, 1994
33. Fisher B
Conservative Surgery : the American experience. *Semin.Oncol.* 13(4):425-433, 1986
34. Liljegren G, Holmberg L, Adami HO, Westman G, Graffman S, Bergh J, Uppsala-Orebro Breast Cancer Study Group
Sector resection with and without postoperative radiotherapy for Stage I breast cancer : 5-Year results of a randomized trial. *JNCI* 86:717-722, 1994
35. Freedman LS, Machin D
Pathology review in cancer research. *Br.J.Cancer* 68:827-830, 1993
36. Kaplan EL, Meier P
Nonparametric estimations from incomplete observations. *Am.Stat.Assoc.J* 53:457-481, 1958
37. Mantel N
Evaluation of survival data and two new rank order statistics arising in its consideration. *Cancer Chemo.Rep.* 50(3):163-170, 1966
38. Ellenberg SS
Surrogate endpoints. *Br.J.Cancer* 68:457-459, 1993
39. Fisher B, Redmond C, Poisson R et al.
Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. *NEJM* 320:822-828, 1989
40. Fraud in Breast-Cancer trials (7 letters)
Fisher B, Redmond CK *NEJM* 330(20):1458-1460, 1994
Poisson R *NEJM* 330(20):1460, 1994
Broder S *NEJM* 330(20):1460-1461, 1994
Bivens LW, MacFarlane DK, *NEJM* 330(20):1461, 1994
Bernier GM *NEJM* 330(20):1461, 1994
Huet PM *NEJM* 330(20):1462, 1994
Richer G *NEJM* 330(20):1462, 1994
41. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA
Risk of second cancers after treatment for Hodgkin's Disease. *NEJM* 318:76-81, 1988
42. Hildreth NG, Shore RE, Dvoretzky PM
The risk of breast cancer after irradiation of the thymus in infancy. *NEJM* 321:1281-1284, 1989
43. Miller AB, Howe GR, Sherman GJ, Lindsay JP, Yaffe MJ, Dinner PJ, Risch HA, Preston DL
Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis. *NEJM* 321:1285-1289, 1989
44. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, Vaughan Hudson B, Bennett MH, MacLennan KA
Risk of second primary cancers after Hodgkin's Disease by type of treatment : analysis of 846 patients in the British National Lymphoma Investigation. *BMJ* 304:1137-1143, 1992
45. Tarbell NJ, Gelber RD, Weinstein HJ, Mauch P
Sex differences in risk of second malignant tumours after Hodgkin's Disease in childhood. *Lancet* 341:1428-1432, 1993
46. Yahalom J, Petrek JA, Biddinger PW, Kessler S, Dershaw DD, McCormick B, Osborne MP, Kinne DA, Rosen PP
Breast cancer in patients irradiated for Hodgkin's Disease : a clinical and pathologic analysis of 45 events in 37 patients. *J.Clin.Oncol.* 10:1674-1681, 1992
47. Hoppe RT, Glatstein E, Wasserman TH
Ch 62: Hodgkin's Disease
in *Principles and Practice of Radiation Oncology*
Perez CA, Brady LW (eds) Second Edition, Lippincott 1992
48. Hunter DJ, Manson JE, Colditz GA, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE, Willett WC
A prospective study of the intake of vitamins C, E and A and the risk of breast cancer. *NEJM* 329:234-240, 1993
49. Coates M, McCredie M, Taylor R
Cancer in New South Wales Incidence and Mortality 1991. NSW Cancer Council, 1994
50. Gilbertsen VA, Church TR, Grewe FJ, Mandel JS, McHugh RB, Schuman LM, Williams SE
The design of a study to assess occult-blood screening for colon cancer. *J.Chron.Dis.* 33:107-114, 1980
51. Ashby D, Machin D
Stopping rules, interim analysis and data monitoring committees. *Br.J.Cancer* 68:1047-1050, 1993
52. Greenberg ER et al., for the Polyp Prevention Study Group
A clinical trial of antioxidant vitamins to prevent colorectal adenoma. *NEJM* 331(3):141-147, 1994
53. Colditz GA, Willett WC, Stampfer MJ
Menopause and risk of coronary heart disease in women. *NEJM* 316:1105- , 1987
54. Recommended Dietary Intakes.
National Health and Research Medical Council, 1982-1988
55. Hennekens CH, Buring JE, Mayrent SL (ed)
Epidemiology in Medicine.

Little Brown & Co, Boston , 1987

56. Bonadonna G, Brusamolino E, Valagussa P
Combination chemotherapy as an adjuvant treatment in operable breast cancer.
NEJM 294:405-410, 1976

57. Fisher B, Carbone P, Economon SG
L-phenylalanine mustard (L-PAM) in the management of primary breast cancer : a report of early findings.
NEJM 292:117-122, 1975

58. Bonnadonna G, Valagussa P, Zambetti M, Buzzoni R, Moliterni A
Milan adjuvant trials for Stage I-II breast cancer.
in Adjuvant Therapy of Cancer V, Salmon SE (ed)
Grune & Stratton, 1987

59. Adjuvant tamoxifen in the management of operable breast cancer : the Scottish trial
Breast Cancer Trials Committee
Lancet 2:171-175, 1987

60. Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M, Gallus G, Greco M, Luini A, Manibini E, Muscolini G, Rilke F, Salvatore B, Zecchini A, Zucali R
Comparing radical mastectomy with quadrantectomy, axillary dissection and radiotherapy in patients with small cancers of the breast.
NEJM 305:6-11, 1981

61. Fisher B, Redmond C, Fisher E et al.
Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with and without radiation.
NEJM 312:674-681, 1985

62. Pierce LJ, Glatstein E
Postmastectomy radiotherapy in the management of operable breast cancer.
Cancer 74:477-485, 1994

63. Valagussa P, Bonadonna G, Veronesi U
Patterns of relapse and survival following radical mastectomy.
Cancer 41:1170-1178, 1978

64. Steel GG, Adams GE, Horwich A (eds)
The Biological Basis of Radiotherapy
Second Edition, Elsevier, Amsterdam, 1989

65. Gelber RD, Goldhirsch A
Can a clinical trial be the treatment of choice for patients with breast cancer?
JNCI 80(12):886-887, 1988